Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 12, 2025 08:00 ET | Source: Quantum BioPharma

Quantum BioPharma Announces Completion of Dosing in 90-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-MS for Multiple Sclerosis

TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a...
April 22, 2025 07:00 ET | Source: Quantum BioPharma

Quantum Biopharma Announces Advocate Against Naked Short Selling and Stock Manipulation, Kevin Malone Appointed as Board Advisor

TORONTO, April 22, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce the appointment of Kevin...
April 02, 2025 08:00 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial

NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
April 01, 2025 02:00 ET | Source: Quantum BioPharma

Quantum BioPharma Announces Joint Clinical Study With Massachusetts General Hospital Scientists to Validate a Novel Positron Emission Tomography (PET) Imaging Technique to Monitor Demyelination In Multiple Sclerosis

TORONTO, April 01, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) “Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a...
March 31, 2025 07:00 ET | Source: Quantum BioPharma

Quantum Biopharma Announces Closing of Final $2.42 Million Tranche of $5 Million Total Financing on Improved Terms

TORONTO, March 31, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”) is pleased to announce that it has closed the final...
February 24, 2025 07:59 ET | Source: Posit Science

Study: Brain Exercise Lowers Fatigue Symptoms in Multiple Sclerosis

SAN FRANCISCO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Researchers at New York University (NYU) found that a particular set of brain exercises lowered the incidence of the all-too-common symptom of...
January 22, 2025 16:05 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab

NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
December 10, 2024 09:00 ET | Source: ADIA Nutrition

Adia Nutrition Opens Doors in Winter Park, FL, Now Accepting Patients for AHSCT and Regenerative Therapies

WINTER PARK, Fla., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Adia Nutrition is thrilled to announce the opening of its inaugural clinic in Winter Park, Florida. The state-of-the-art facility is now...
December 04, 2024 07:00 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional Prestigious U.S. Medical Centers

NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
November 21, 2024 09:00 ET | Source: DANNCE.AI

DANNCE.AI Raises $2.6 Million; Launches to Provide Clinicians and Drug Developers an AI Biomarkers Platform to Characterize Drug Effects and Optimize Neurological Care

DANNCE.AI Raises $2.6 Million; Launches to Provide Clinicians and Drug Developers an AI Biomarkers Platform.

Next Page keyboard_arrow_right